NCT02589496View on ClinicalTrials.gov

Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 26, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

pembrolizumab

200 mg every 3 weeks

Trial Locations (1)

135-720

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02589496 - Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis | Biotech Hunter | Biotech Hunter